GLP-1RAs and DPP-4 inhibitors were assessed in only 1 study for subgroup analysis on patients with T2DM, therefore more trials including patients with only T2DM without any comorbidities should be conducted to further improve the analysis and compare the effect of three-novel glucose agents for patients with T2DM better. Here, DPP4 is linked to type 2 diabetes mellitus.